Symbiotec Pharmalab IPO Review
Symbiotec Pharmalab Limited, a company with a strong global leadership position in Corticosteroid and Steroidal Hormone Active Pharmaceutical Ingredients, plans to raise INR 1,757 crore through an IPO.
[Fresh Issue ₹150 Cr + OFS ₹1,607 Cr]
Symbiotec Pharmalab IPO price: ₹938–₹988 per share
Symbiotec Pharmalab: History
The Company was incorporated as Symbiotec Pharmalab Private Limited as a private limited company under the Companies Act, 1956, on September 20, 2002.
The Company was then converted into a public limited company on September 12, 2025, under a special resolution passed by the shareholders.
Its name was subsequently changed to Symbiotec Pharmalab Limited, and the Registrar of Companies (RoC) issued a fresh certificate of incorporation on September 26, 2025.
Symbiotec Pharmalab: Business
Symbiotec Pharmalab Limited is a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms –
- Organic chemistry,
- Biotechnology, and
- Complex injectables.
The Company has a robust product portfolio of over 60 corticosteroid and steroidal hormone APIs supplied globally, used extensively in critical care settings and across chronic therapeutic areas such as respiratory, dermatology, pain management, oncology, and gynaecology.
Symbiotec serves over 200 clients across 40 countries, including pharmaceutical companies in the US, Europe, and Asia.
Leadership Position
The Company holds a global leadership position in corticosteroid (volume market share of 36.2%) and steroidal-hormone (volume market share of 44.2%) active pharmaceutical ingredients (APIs) in Fiscal 2025.
According to the F&S Report, Symbiotec is the only Indian and global company with a presence across the top 10 corticosteroid and steroidal hormone APIs in FY25.
Global Approvals
The Company has evolved from a lab-scale steroidal-hormone API manufacturer in 1995 into an industrial-scale, backward-integrated platform with approvals from –
- The United States Food and Drug Administration (USFDA),
- European Union Good Manufacturing Practices (EU-GMP),
- Ministry of Food and Drug Safety (Korea), and
- Other global organisations.
Strategies Ahead
Build on global leadership by expanding product portfolio across steroidal hormones in API and ingredients business.
Build on fermentation capabilities and expand biotechnology offerings (such as GLP-1 and Insulin).
Commercialize complex injectables through differentiated drug-device combinations.
Scale up diverse CDMO offerings.
Invest in new technologies and R&D for optimising products.
Partner with large companies for difficult-to-execute projects.
Company Promoters
- Anil Satwani,
- Kashish Satwani,
- Sushil Satwani,
- Satwani Holdings LLP.
Refer to Symbiotec Pharmalab DRHP for more information.
IPO Detail
ipo date: 24 Aug – 27 Aug 2026
Minimum Amount: ₹14,820
Minimum Bid: 15 Shares
Face Value: INR 2 per share
Listing On: NSE, BSE
Financial
Book Running Lead Managers
Avendus Capital,
JM Financial,
Motilal Oswal Investment Advisors,
Nomura Financial Advisory and Securities.
CONCLUSION
Considering financial performance and the nature of the business, FinBlab recommends ‘NEUTRAL‘ ratings for the Symbiotec Pharmalab Limited IPO.
Do come back to learn more about “upcoming IPOs”.
================================================================================
Disclaimer: This article is purely for informational purposes.
While much time and effort is made to provide the information, I (Vishal Dalwadi) or (FinBlab) do not guarantee the accuracy, correctness, completeness or reliability of any information or data displayed herein and shall not be held responsible.
